


If this message is not displayed correctly, please visit the [webversion](#).



A testing bed for the development of high-risk medical devices.

## Newsletter Issue N° 3

Dear reader,

With this issue, we welcome you to our first special edition with a focus on the five steps to develop a medical device. Providing a full set of services to guide developers in the process is TB MED's major goal. To this end, TB MED intends to prepare a set of tutorials in the future to give developers direction and hands-on advice. Find out more about what is coming next in this newsletter.


### The five phases of developing a medical device

It has never been easy to develop a medical device (MD). This is particularly true for high-risk medical devices affected by the EU's current [regulation 2017/745](#).

The entire process of developing such a device can be divided into different phases with particular tasks to be performed to reach the specific objectives. In a combined effort of different institutions, TB MED is aiming to provide a full set of high-quality services covering all development steps starting at [TRL3 up to TRL7](#).

This includes the following five phases:

#### 1. Concept Phase




Technology transfer is a core activity of this phase in order to check reproducibility of the device. However, a market analysis & regulatory roadmap should also be prepared at this stage to ensure viability.

#### 2. Prototype Optimization


In this phase, we do not only optimize the prototype and its manufacturing process, but we also propose a Quality Control (QC) strategy and a biological evaluation plan. A Health Technology Assessment (HTA) meeting is held to verify the alignment of the device with the current market needs.

Remember that TB MED has a strong focus on **Quality by Design** (QbD)! Applying the QbD methodology can help to optimize the time and cost of the device development. In addition, it could improve the robustness of the manufacturing process.



■ Look out for our tutorial on QbD!  
It is planned to go public on the website in May 2021.

#### 3. Prototype Validation




This phase includes the scaling up of the manufacturing process under ISO13485-like conditions as well as different *in vitro* and *in vivo* tests under GLP to prove the safety and efficacy of the device. A second HTA meeting will help to define the end points for the clinical studies as well as different aspects to take into account for the reimbursement process.

■ Look out for our support material on HTA meetings. It is planned to go public on the website in the course of April 2021.

#### 4. Clinical Proof of Concept

In order to continue with the validation of the device a small clinical study (Clinical Proof of Concept) must be carried out. TBMED will help with all the documentation, submission and approval processes of the regulatory bodies. A follow-up of the study will also be done. A risk analysis constitutes a mandatory part of this documentation. In our experience, companies have many doubts on how to perform it. Inside TBMED we have experts who can help you with it.



■ A tutorial with advice on how to approach a risk analysis is planned to go public on the website in June 2021.

#### 5. Clinical Investigations



Finally, once the first results are obtained, a larger clinical trial, in some cases multinational, could be required. TBMED will help with all the related topics such as documentation, submission and approval processes of the regulatory bodies.

#### Upcoming events



**MedTechForum** - Online event taking place on April 20-22, 2021

**EuroNanoForum** - Online conference taking place on May 5-6, 2021

■ Stay tuned about future events.

We hope that you enjoyed our special edition. Follow us on Twitter and visit our website for the upcoming tutorials.



TBMED on Twitter

*Impressum:  
Eurice - European Research and Project Office GmbH  
Heinrich-Hertz-Allee 1  
66386 St. Ingbert  
Unsubscribe from our newsletter*

